Alcohol Use DisorderNCT06286449
Identification of Cellular and Molecular Mechanisms Involved in the Pathophysiology of Alcohol Use Disorder by Examination of Cerebrospinal Fluid
A study testing Spinal tap in people with Alcohol Use Disorder, run by Vastra Gotaland Region at 1 site in Sweden.
Trial summary
BACKGROUND The brain and spinal cord are enveloped by cerebrospinal fluid (CSF), which extends down to the base of the spine, a few centimeters below the termination of the spinal cord. Here, it can be collected through a minor needle puncture. Read more about this study
- Who is it for?
- Ages 18 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Alcohol Use Disorder
- What is being tested?
- Spinal tap
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteSweden
- Study dates
- 1 Mar 2024to 31 Dec 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- The study participant:
- has given his/her written and oral informed consent to participate in the study
- presents a breath alcohol concentration (BrAC) below 10mg% (10mg/dl) at the study visit
Who cannot join
- The study participant:
- is pregnant or breastfeeding
- has an ongoing neurological or psychiatric disease except for Alcohol Use Disorder
- has an ongoing or previous disease that affects either the safety of the study participant following a spinal tap or the outcome measures of the study
- currently uses (within 30 days of enrollment) medication that affects either the safety of the study participant following a spinal tap or the outcome measures of the study
- currently uses (within 30 days of enrollment) medications for the treatment of Alcohol Use Disorder or alcohol abstinence that affects the mesolimbic dopamine system
Show all 14Show fewer
- currently uses (within 30 days of enrollment) dietary supplements, including energy drinks, that may affect the safety for the study participant following a spinal tap or may have an impact on the outcome measures
- 8. currently and frequently uses (within 1 year of enrollment) drugs of abuse other than alcohol and nicotine.
- 9. participates in another interventional clinical trial within 30 days of enrollment
- 10. has a local infection or a tattoo in the lower back region
- 11. anatomical anomalies in the lower spine region, e.g. following prior spine surgery, that obstructs the procedure of a spinal tap
- 12. has prior history of allergic reactions to local anaesthetics
- 13. presents pathological findings during medical examination that may affect the safety for the study participant following a spinal tap or the outcome measures
- 14. is considered to be unfit for study participation for other reasons than stated above
Trial locations and contacts
1 site in 1 country.
Sweden1 site
Sahlgrenska Universitetssjukhuset
Gothenburg, Västra Götaland County, 405 30
About this study
BACKGROUND
The brain and spinal cord are enveloped by cerebrospinal fluid (CSF), which extends down to the base of the spine, a few centimeters below the termination of the spinal cord. Here, it can be collected through a minor needle puncture. This procedure enables the gathering of information about otherwise concealed molecular and cellular processes in the brain. Analyzing various specific molecules in the CSF has yielded crucial insights into the underlying mechanisms of many neurological and psychiatric disorders, such as multiple sclerosis (MS) and dementia, significantly enhancing the prospects for its treatment. However, for several brain disorders, including Alcohol Use Disorder (AUD) and substance use disorders, CSF studies are absent. AUD, a brain disease affecting the reward system, is characterized by an inability to limit alcohol consumption. High levels of alcohol intake, as seen in AUD, are a leading cause of morbidity and premature mortality. Yet, there is a lack of effective medications for its treatment. Analyzing molecules in CSF, believed to be significant for the development and maintenance of AUD, could enhance the development of effective pharmacological treatments. At present, there are no CSF studies on individuals with AUD, that explore the underlying mechanisms of the disease. Additionally, several CSF studies lack a representative control group of truly healthy controls (i.e. have not presented any neurological or psychiatric symptoms), which is crucial for drawing accurate conclusions.
Read more
OBJECTIVE
Sub-study 1 aims to collect CSF from individuals with AUD across various ages to analyze brain molecules that contribute to the development and maintenance of the disease.
Sub-study 2 aims to gather CSF from healthy controls across various ages to study molecules involved in neurological and psychiatric conditions, including AUD, substance dependency, brain inflammation, and narcolepsy. The goal is to create a reference group of CSF from healthy controls for comparison with CSF collected from individuals with the aforementioned conditions.
We hypothesize that levels of certain molecules, such as dopamine, differ between healthy controls and those with e.g. AUD. This study may provide insights into cellular and molecular mechanisms underlying brain disorders, which is in turn crucial for developing new, effective treatments.
Sub-study 3 will examine how the incubation of nerve cells in CSF collected in sub-study 1 and 2 affects their excitability and ability to form new synapses, essential for communication in the brain.
We hypothesize that the excitability and synaptogenesis of nerve cells will vary depending on whether they are incubated in CSF from neurologically and psychiatrically healthy individuals versus those with AUD, substance use disorders, brain inflammation, and narcolepsy. Understanding how CSF composition influences brain function in these conditions could be instrumental in creating new therapeutic drugs.
METHODS
Individuals with AUD, as well as psychiatrically and neurologically healthy volunteers, will be successively recruited for CSF collection and analyses. Recruitment will be performed through media advertisements and posters within healthcare facilities (The Sahlgrenska University Hospital) and the University of Gothenburg. Additional participants will be recruited from parallel research projects performed within the group (IV-ASA BO10 dnr: 2019-04120, COMB BO8 dnr 431-18, GlycinA BO5 dnr 806-14, PI Bo Söderpalm and NordAlc BO9 dnr: 430-18, PI Andrea de Bejczy) CSF will be obtained through lumbar puncture (spinal tap), a procedure where a thin needle is inserted below the end of the spinal cord. Local anesthesia will be administered in order to mitigate potential discomfort. The lumbar puncture will be performed by an experienced physician, minimizing the risk of injury. Blood samples will also be collected to correlate molecule levels in CSF with those in the blood. Participants will be interviewed about their medical history including their alcohol consumption, and a comprehensive medical examination will be performed.
SIGNIFICANCE
CSF studies offers unique insights into the cellular and molecular processes within the brain. This approach has been utilized for exploring the mechanisms behind several psychiatric and neurological disorders, but not for certain brain diseases like AUD. AUD inflicts significant suffering for affected individuals, contributes to high mortality rates, and imposes considerable burdens on the society. Moreover, a deeper understanding of the cellular and molecular underpinnings of brain diseases such as AUD, can facilitate the development of novel, more effective medications for its treatment.
- Conditions
- Alcohol Use Disorder
- Being tested
- Spinal tap
- Medical subject headings
- Alcoholism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Spinal tapOther
Also called Lumbar puncture
A spinal tap is performed on all enrolled study participants that meet the eligibility criteria
| Study group | Role | What they receive |
|---|---|---|
| Alcohol Use Disorder cohort and Healthy controls cohort | Other | Alcohol Use Disorder Cohort The intervention, which all participants from both cohorts undergo, consists of a spinal tap, in which 35 ml of cerebrospinal fluid is collected for further analysis and comparison between a cohort consisting of healthy controls. Study participants with Alcohol Use Disorder (AUD) are recruited from other previous or ongoing clinical trials performed within the research group: NordAlc (PI Andrea de Bejczy), IV-ASA (PI Bo Söderpalm), GlycinA (PI Bo Söderpalm) and COMB (PI Bo Söderpalm).
Healthy controls cohort The intervention, which all participants from both cohorts undergo, consists of a spinal tap, in which 35 ml of cerebrospinal fluid is collected for further analysis and comparison between a cohort consisting of participants with Alcohol Use Disorder. Healthy controls will be continuously recruited via advertisements in media, and onsite at the Sahlgrenska University Hospital and the University of Gothenburg Receives: Other: Spinal tap |
What is being measured
The primary outcome is the main question the study is designed to answer.
CSF-DA levels
Levels of dopamine in the cerebrospinal fluid
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Feb 2024
- Study start1 Mar 2024
- Primary completion31 Dec 2028 (estimated)
- Study completion31 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alcohol Use DisorderStudies of the same condition, open and under way.
- More trials run by Vastra Gotaland RegionThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- The intervention in this study consists of a spinal tap that all study participants undergo. We are comparing biomarkers in cerebrospinal fluid collected from either participants with Alcohol Use Disorder or from healthy controls.
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Vastra Gotaland Region
- Sponsor type
- Other government
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06286449
- Sponsor's protocol ID
- CSV_AUD
- Status last verified
- Sep 2026
- First submitted
- 22 Feb 2024
- Last updated
- 9 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The ethical approval does not allow us to share individual patient data, but only data presented on a group level, so that no individual patient can be identified.
Study at a glance
From the registry record, last updated by the sponsor on 9 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Identification of Cellular and Molecular Mechanisms Involved in the Pathophysiology of Alcohol Use Disorder by Examination of Cerebrospinal Fluid
- ClinicalTrials.gov ID
- NCT06286449
- Acronym / sponsor ID
- CSV_AUD
- Conditions
- Alcohol Use Disorder
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Vastra Gotaland RegionOther government
- Study start
- 1 Mar 2024 (actual)
- Primary completion
- 31 Dec 2028 (estimated)
- Study completion
- 31 Dec 2028 (estimated)
- First posted
- 29 Feb 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
BACKGROUND
The brain and spinal cord are enveloped by cerebrospinal fluid (CSF), which extends down to the base of the spine, a few centimeters below the termination of the spinal cord. Here, it can be collected through a minor needle puncture. This procedure enables the gathering of information about otherwise concealed molecular and cellular processes in the brain. Analyzing various specific molecules in the CSF has yielded crucial insights into the underlying mechanisms of many neurological and psychiatric disorders, such as multiple sclerosis (MS) and dementia, significantly enhancing the prospects for its treatment. However, for several brain disorders, including Alcohol Use Disorder (AUD) and substance use disorders, CSF studies are absent. AUD, a brain disease affecting the reward system, is characterized by an inability to limit alcohol consumption. High levels of alcohol intake, as seen in AUD, are a leading cause of morbidity and premature mortality. Yet, there is a lack of effective medications for its treatment. Analyzing molecules in CSF, believed to be significant for the development and maintenance of AUD, could enhance the development of effective pharmacological treatments. At present, there are no CSF studies on individuals with AUD, that explore the underlying mechanisms of the disease. Additionally, several CSF studies lack a representative control group of truly healthy controls (i.e. have not presented any neurological or psychiatric symptoms), which is crucial for drawing accurate conclusions.
OBJECTIVE
Sub-study 1 aims to collect CSF from individuals with AUD across various ages to analyze brain molecules that contribute to the development and maintenance of the disease.
Sub-study 2 aims to gather CSF from healthy controls across various ages to study molecules involved in neurological and psychiatric conditions, including AUD, substance dependency, brain inflammation, and narcolepsy. The goal is to create a reference group of CSF from healthy controls for comparison with CSF collected from individuals with the aforementioned conditions.
We hypothesize that levels of certain molecules, such as dopamine, differ between healthy controls and those with e.g. AUD. This study may provide insights into cellular and molecular mechanisms underlying brain disorders, which is in turn crucial for developing new, effective treatments.
Sub-study 3 will examine how the incubation of nerve cells in CSF collected in sub-study 1 and 2 affects their excitability and ability to form new synapses, essential for communication in the brain.
We hypothesize that the excitability and synaptogenesis of nerve cells will vary depending on whether they are incubated in CSF from neurologically and psychiatrically healthy individuals versus those with AUD, substance use disorders, brain inflammation, and narcolepsy. Understanding how CSF composition influences brain function in these conditions could be instrumental in creating new therapeutic drugs.
METHODS
Individuals with AUD, as well as psychiatrically and neurologically healthy volunteers, will be successively recruited for CSF collection and analyses. Recruitment will be performed through media advertisements and posters within healthcare facilities (The Sahlgrenska University Hospital) and the University of Gothenburg. Additional participants will be recruited from parallel research projects performed within the group (IV-ASA BO10 dnr: 2019-04120, COMB BO8 dnr 431-18, GlycinA BO5 dnr 806-14, PI Bo Söderpalm and NordAlc BO9 dnr: 430-18, PI Andrea de Bejczy) CSF will be obtained through lumbar puncture (spinal tap), a procedure where a thin needle is inserted below the end of the spinal cord. Local anesthesia will be administered in order to mitigate potential discomfort. The lumbar puncture will be performed by an experienced physician, minimizing the risk of injury. Blood samples will also be collected to correlate molecule levels in CSF with those in the blood. Participants will be interviewed about their medical history including their alcohol consumption, and a comprehensive medical examination will be performed.
SIGNIFICANCE
CSF studies offers unique insights into the cellular and molecular processes within the brain. This approach has been utilized for exploring the mechanisms behind several psychiatric and neurological disorders, but not for certain brain diseases like AUD. AUD inflicts significant suffering for affected individuals, contributes to high mortality rates, and imposes considerable burdens on the society. Moreover, a deeper understanding of the cellular and molecular underpinnings of brain diseases such as AUD, can facilitate the development of novel, more effective medications for its treatment.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- The intervention in this study consists of a spinal tap that all study participants undergo. We are comparing biomarkers in cerebrospinal fluid collected from either participants with Alcohol Use Disorder or from healthy controls.
| Arm | Type | Receives |
|---|---|---|
| Alcohol Use Disorder cohort and Healthy controls cohort | Other | Other: Spinal tapAlcohol Use Disorder Cohort The intervention, which all participants from both cohorts undergo, consists of a spinal tap, in which 35 ml of cerebrospinal fluid is collected for further analysis and comparison between a cohort consisting of healthy controls. Study participants with Alcohol Use Disorder (AUD) are recruited from other previous or ongoing clinical trials performed within the research group: NordAlc (PI Andrea de Bejczy), IV-ASA (PI Bo Söderpalm), GlycinA (PI Bo Söderpalm) and COMB (PI Bo Söderpalm). Healthy controls cohort The intervention, which all participants from both cohorts undergo, consists of a spinal tap, in which 35 ml of cerebrospinal fluid is collected for further analysis and comparison between a cohort consisting of participants with Alcohol Use Disorder. Healthy controls will be continuously recruited via advertisements in media, and onsite at the Sahlgrenska University Hospital and the University of Gothenburg |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- has given his/her written and oral informed consent to participate in the study
- presents a breath alcohol concentration (BrAC) below 10mg% (10mg/dl) at the study visit
Key exclusion criteria (14 listed)
- is pregnant or breastfeeding
- has an ongoing neurological or psychiatric disease except for Alcohol Use Disorder
- has an ongoing or previous disease that affects either the safety of the study participant following a spinal tap or the outcome measures of the study
- currently uses (within 30 days of enrollment) medication that affects either the safety of the study participant following a spinal tap or the outcome measures of the study
- currently uses (within 30 days of enrollment) medications for the treatment of Alcohol Use Disorder or alcohol abstinence that affects the mesolimbic dopamine system
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Spinal tapAlso: Lumbar punctureA spinal tap is performed on all enrolled study participants that meet the eligibility criteria | Other | Alcohol Use Disorder cohort and Healthy controls cohort |
Primary outcome
CSF-DA levels
Time frame: 3 years
Levels of dopamine in the cerebrospinal fluid
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Sep 2026.
- Individual participant dataSharing planned: No. The ethical approval does not allow us to share individual patient data, but only data presented on a group level, so that no individual patient can be identified.
Related trials for Alcohol Use Disorder
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruiting
Substance Use and Media Preferences
Substance Use Behavior, Cannabis Intoxication
RecruitingPhase 1
Environment and Alcohol: A Pilot Study
Alcohol Use Disorder
RecruitingObservational study
SMART-r: Substance Monitoring and Active Relapse Tracking Repository
Alcoholism, Substance-Related Disorders
Not yet recruiting
A MRT to Optimize a JITAI for Alcohol Craving and Suicide Ideation
Alcohol Use Disorder (AUD), Suicide Ideation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Spinal tap in people with Alcohol Use Disorder, run by Vastra Gotaland Region at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 9 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
CSF-DA levels (time frame: 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2026.